Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

Bologna (Italy), 4 November 2016.

Cellply announced today that the results of a scientific collaboration with hematologists at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy) working on Acute Myeloid Leukemia (AML), a group led by Prof. Giovanni Martinelli, will be presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 3-6 in San Diego, CA, USA. “This is a key milestone for our company as it shows the potential of the Open Microwell technology and the IVD platform under development at Cellply to become an important tool for guiding the identification of the appropriate treatment for each patient or patient set through the analysis of biological information that today remain mostly not exploited for patient stratification”, says Massimo Bocchi, CEO of Cellply. “The preliminary data collected within this scientific activity provided good correlation between our test and the clinical outcome, making Cellply’s platform promising for predicting the haematological response, an endpoint of primary importance not only from a clinical standpoint but also for its use within clinical trials”, added Laura Rocchi, Head of Biology at Cellply. The following abstract was accepted for poster presentation by the American Society of Hematology.

Title: Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform
Authors: Laura Rocchi, Andrea Faenza, Laura Rambelli, Viviana Guadagnuolo, Giovanni Marconi, Giorgia Simonetti, Cristina Papayannidis, Antonella Padella, Nicola Pecorari, Luca Giulianelli, Dario Biscarini, Giovanni Martinelli, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 1675
Date/Time: Saturday, December 3, 2016, 5:30 PM-7:30 PM
Location: Hall GH (San Diego Convention Center)
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I

Link to abstract on ASH website


Cellply wins an H2020 SME Instrument Phase 1 grant

Bologna (Italy) – Bruxelles (Belgium), 20 October 2016

Cellply has recently been awarded by the European Commission as winner of a SME Intrsument Phase 1 grant within the Horizon 2020 programme. The ONCOSMART (ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics) project aims at developing an innovative platform for precision medicine, able to profile each cancer patient by analyzing how one or multiple candidate drugs interact with patient’s cells. The innovative test works by extracting a tumor sample and loading it in the platform readily after sampling, while cells are still alive. The ability of the drug to kill tumor cells is then analyzed and personalized response profiles are created. The platform, consisting of a lab-on-a-chip embedded in disposable cartridge, an analytical instrument and a diagnostic software, provides a result in 24 hours and aims at guiding clinicians in selecting the optimal therapy on a patient-by-patient basis and at supporting drug development companies during clinical development of new drugs. The project will allow Cellply to perform a feasibility study, explore business opportunities and regulatory issues/opportunities, identify a supply chain and set the basis for the development of a new in-vitro diagnostic (IVD) platform.